Dynamics of colistin and tobramycin resistance among Enterobacter cloacae during prolonged use of selective decontamination of the digestive tract

Table 1 Antibiotic resistance in patients with resistant E. cloacae and susceptible E. cloacae

Antibiotic (combination)	Susceptible E. cloacae (n = 2075 unique patients, 3030 isolates)		Multi-resistant E. cloacae (n = 373 patients, 1373 isolates)		Selected for WGS (n = 112 isolates)
Antibiotic (combination)	Patients (n) tested	% non-susceptible / positive^a	Patients (n) tested	% non- susceptible / positive^a	% non- susceptible / positive^a
ciprofloxacin	2075	1.3	373	42.9	28.6
colistin	1122	0	205	68.8	78.4^b
gentamicin	2075	0.2	373	82.8	86.6
imipenem	2070	0.2	373	5.6	6.3
meropenem	2073	0.1	373	4.8	6.3
tobramycin	2075	0	373	89.3	87.5
trimethoprim/ sulfamethoxazole	2075	5.5	373	34.6	86.6
ESBL production	873	0	156	71.2	72.3
CIP or SXT	2075	0.6	373	17.7	5.4
CIP or SXT or MEM	2064	0	349	0.9	0
CIP or SXT or MEM or CST	1118	0	187	0.5	0

CIP ciprofloxacin, CST colistin, ESBL extended-spectrum beta-lactamase, MEM meropenem, n number, SXT trimethoprim/ sulfamethoxazole, WGS whole-genome sequencing
^a% non-susceptible for antibiotics or % ESBL positive
^b111/112 isolates tested
Number of resistant E. cloacae isolates tested: ciprofloxacin: n = 1373, colistin: n = 784, gentamicin: n = 1373, imipenem: n = 1373, meropenem: n = 1371, tobramycin: n = 1373, trimethoprim/ sulfamethoxazole: n = 1372. Number of susceptible E. cloacae isolates tested: ciprofloxacin: n = 3030, colistin: n = 1613, gentamicin: n = 3030, imipenem: n = 3024, meropenem: n = 3028, tobramycin: n = 3030, trimethoprim/ sulfamethoxazole: n = 3030

ISSN: 2047-2994